## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.8% in lower entry zone (4.0-10.0%), top quartile (84th pct) cross-sectional ranking. Short-term MRS_5 (1.9%) confirms momentum alignment. Outperforming sector by 9.1%. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($81.57)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: The Olympian | 20251210T140759 | Bullish | Relevance: 99%
-  Sant' Andrea University Hospital is partnering with GE HealthCare and Tribun Health to integrate their enterprise imaging and digital pathology solutions. This collaboration aims to unify radiology and pathology into an AI-ready environment, specifically enhancing data-driven cancer care by streamlining diagnostics and improving multidisciplinary collaboration. The initiative, partially funded by the National Recovery and Resilience Plan, is a significant step in the hospital's digital transformation to accelerate informed decisions for cancer patients.

**2. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: Tallahassee Democrat | 20251211T040827 | Bullish | Relevance: 99%
-  Sant' Andrea University Hospital is set to integrate GE HealthCare's Enterprise Imaging platform and Tribun Health's CaloPix® digital pathology solution. This collaboration aims to unify radiology and pathology into an AI-ready environment, accelerating diagnostics and improving cancer patient outcomes. The investment, partially funded by the National Recovery and Resilience Plan, positions Sant' Andrea at the forefront of data-driven cancer care in Lazio.

**3. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: The AI Journal | 20251209T150812 | Bullish | Relevance: 98%
- The AI-powered medical devices market is projected to reach $59.84 billion by 2032, growing at a CAGR of 18.26% from $15.64 billion in 2024. This growth is driven by technological integration and expanded adoption across clinical environments, with key players including GE HealthCare Technologies, Siemens Healthineers, and Philips. The report highlights AI's role in diagnostics, monitoring, and treatment, emphasizing its impact on medical workflows and operational efficiency.

**4. New Healthcare Leaders Emerge. 3 Stocks With Bullish Charts.**
- Source: Barron's | 20251209T163409 | Bullish | Relevance: 98%
-  Several non-biotech healthcare stocks are showing significant momentum, breaking out of their bases and establishing themselves as sector leaders. With improving volume, accelerating relative strength, and clean technical setups, these medical technology, services, and equipment stocks are poised for continued strong performance. The article highlights GE Healthcare, STERIS, and Hinge Health.

**5. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: The News Journal | 20251211T050832 | Bullish | Relevance: 98%
-  Sant' Andrea University Hospital, affiliated with Sapienza University of Rome, will integrate GE HealthCare's Enterprise Imaging platform with Tribun Health's CaloPix® digital pathology solution. This collaboration aims to unify radiology and pathology into an AI-ready environment, accelerating diagnostics and improving cancer patient outcomes. The hospital is the first in Lazio to implement full digital pathology, supported by significant investment.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 17.4x stretched relative to 9% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.3B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 17.4 |
| Current P/E | 18.9 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.7% to 6.8% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 84th percentile. MRS_5 at 1.9% confirms short-term momentum alignment. AM_20 at 9.0% shows strong absolute momentum above own 20MA. Outperforming sector by 9.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.77% (CS: 85) | Strong |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.090x | Above |
| vs SMA50 | 1.123x | Above |
| vs SMA200 | 1.154x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $86.05
- **Stop Loss:** $81.57 (5.2% risk)
- **Target:** $92.77 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 308
- **Position Value:** $26,503.40
- **Portfolio %:** 26.50%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*